HugoScore hugoscore.org

Symptom assessment AI

Ada Health

Ada’s direct assessments differ from partner-controlled sharing and decisions. Its US policy describes consented health-derived marketing segments. Removing an existing segment requires a separate request, beyond changing the consent setting.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Leans expands8 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Leans expands 8 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Direct Ada symptom assessment (Ada Assess) used by the patient on ada.com or the Ada app. Partner-embedded Assess and the US advertising-segment consent are distinguished in notes.

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Not independently replicated
Ada Assess is an AI software application that uses custom probabilistic reasoning technology on a medical-expert-curated knowledge base Source

Terms section 1.3 also describes 'an in-house developed, artificial intelligence (AI) model'. Last modified 6 Nov 2025.

2. Operator and model maker namedYesdocumented
Not independently replicated
Ada utilizes the services of Together AI, a third party LLM Source

Ada Health, Inc. (US) and Ada Health GmbH are named. The core model is Ada's own PGM. Together AI (LLM) and Microsoft Azure (free-text input) are named.

3. Patient chooses to use itYesdocumented
Not independently replicated
Ada Assess is available for free via our website and (when and where available) via websites/apps of business partners. Source

Direct use is the user's choice. In partner-embedded versions the partner chooses to deploy it, and I did not assess that variant.

4. Patient sets the taskYesdocumented
Not independently replicated
to provide Users with health information relevant to medical findings they are currently experiencing Source

The user supplies the symptoms. The fixed function is symptom assessment, with Ada's questions and an optional partner-care step.

5. Patient can decline or stopYesdocumented
Not independently replicated
You are entitled to stop using this website, Ada Assess, Ada PHC and your User Account at any time Source

Self-started tool per the Q3 source, no care depends on it.

6. Patient sees the AI outputYesdocumented
Not independently replicated
the User is provided with a report that lists such information as the conditions likely to be causing these findings Source

The Ada Health GmbH policy says the report can be downloaded to the device.

7. Patient can correct or challengeNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

The policies list GDPR/CCPA rights to rectify personal data, but no route to correct or contest the assessment output is documented.

8. Patient can get a copyYesdocumented
Not independently replicated
You are not required to receive the report this way and can instead download the report onto your device. Source

This is the Ada Health GmbH (app) policy. It also lists data portability rights.

9. Patient can deleteYesdocumented
Not independently replicated
you may request the deletion of a specific case or delete the case yourself Source

The GmbH policy says data is deleted or irreversibly anonymized within 1 month. The US terms say deactivation deletes personal data but Ada keeps rights to anonymized data.

10. Training or sale does not override patient choiceNodocumented
Not independently replicated
To improve our Services, as well as for training and quality purposes Source

The US policy says third-party LLMs will not train on user data. But terms 5.2 say Ada uses Together AI 'for internal AI training', the policy lists developing 'Artificial Intelligence/Large Language Models', and the GmbH policy trains on anonymized assessment data. No opt-out is documented.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted only.

12. No advertising or data businessNodocumented
Not independently replicated
Ada also creates advertising segments which it sells to its marketing partners. Source

US policy section 6.2 makes this consent-based, but the rule counts it even with consent. Terms 3.2 grant Ada a perpetual license to use anonymized data 'in any manner'. Conflict: the GmbH app policy says Ada will 'never share your personal health information with advertisers'. The US policy governs for US users.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

MixedEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Mixed, potentially agency-expanding

Legacy editorial placement, pre-method: 66

This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Ada Health serve in this deployment?
Control Direct Ada symptom assessment (Ada Assess) used by the patient on ada.com or the Ada app. Partner-embedded Assess and the US advertising-segment consent are distinguished in notes.
Agency read Leans expands
Vendor
Ada Health GmbH
Who it serves
Hybrid patient-facing symptom assessment AI
Primary User
Patients, health systems, payers, pharmaceutical companies, and population health programs
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
Reports support reflection and action. Correcting personal data and contesting an institution's consequential decision are separate routes, and actual report-level revision remains untested.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Moderate for policy distinctions (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 66

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 66. Not comparable with v1.3 positions.

Mixed, potentially agency-expanding

Ada’s direct assessments differ from partner-controlled sharing and decisions. Its US policy describes consented health-derived marketing segments. Removing an existing segment requires a separate request, beyond changing the consent setting.

Patient agency

How this tool changes agency

Expands agency when

Reports support reflection and action. Correcting personal data and contesting an institution's consequential decision are separate routes, and actual report-level revision remains untested.

Limits agency when

In-app consent comprehension, report correction and partner alternatives remain unverified

Patient agency assessment

Who sets and changes the goal?

Patient authority

Direct assessment can support self-directed care seeking. Mandatory sharing in some integrations is an actual deployment condition, while partner routing decisions are not attributable to every consumer assessment.

What can the patient understand, question, or do?

Critical capacity

Reports support reflection and action. Correcting personal data and contesting an institution's consequential decision are separate routes, and actual report-level revision remains untested.

Can the patient evaluate the conditions of use?

Informed control

The separate segment-removal action materially affects meaningful withdrawal. Pseudonymization should not be described as the absence of health-derived commercial targeting.

Text findings

Conditions of use

Published controls and their limits

The separate segment-removal action materially affects meaningful withdrawal. Pseudonymization should not be described as the absence of health-derived commercial targeting.

What remains unknown?

Not tested or not established

In-app consent comprehension, report correction and partner alternatives remain unverified

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

In-app consent comprehension, report correction and partner alternatives remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Moderate for policy distinctions (AI-assisted draft)